Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Century Therapeutics’ SEC filings rarely read like simple financial statements. Each 10-K weaves stem-cell science, Allo-Evasion™ gene edits and cash-burn projections into 200+ pages, leaving investors hunting for clear answers. Stock Titan fixes that problem.
Our AI-powered reader turns every Century Therapeutics SEC filing into plain-English insights. Want the latest “Century Therapeutics quarterly earnings report 10-Q filing” summarized before the market opens? We tag key figures—R&D spend, clinical trial milestones, liquidity runway—and deliver context in seconds. Need “Century Therapeutics insider trading Form 4 transactions” alerts? Real-time feeds flag executive stock moves, so you can follow “Century Therapeutics executive stock transactions Form 4” without refreshing EDGAR.
You’ll find every document, from the “Century Therapeutics annual report 10-K simplified” to “Century Therapeutics 8-K material events explained,” all indexed the moment they hit the SEC. Our platform connects forms to what matters for this particular biotech:
- 10-K: Pipeline status, manufacturing capacity and Allo-Evasion™ IP disclosures
- 10-Q: Quarterly cash burn and trial read-outs
- 8-K: Partnership deals, FDA designations and clinical setbacks
- DEF 14A proxy: “Century Therapeutics proxy statement executive compensation” showing R&D incentive structures
- Form 4: “Century Therapeutics Form 4 insider transactions real-time” for sentiment signals before data drops
Stop scrolling through dense PDFs. Stock Titan’s expert analysis, natural-language summaries and adjustable redline comparisons let you understand “Century Therapeutics SEC filings explained simply” and act on them faster.
Century Therapeutics (IPSC) insider transaction: The company’s SVP Finance & Operations reported selling 292 shares of common stock at $0.586 on November 3, 2025.
The filing states these sales were executed to satisfy tax withholding obligations tied to the vesting of restricted stock units and were automatic, not at the reporting person’s discretion. Following the transaction, the insider beneficially owns 405,131 shares, held directly.
Century Therapeutics insider filing reports a grant of restricted stock units to the company’s Chief Scientific Officer. The report shows 762,543 RSUs were granted on 09/18/2025; each RSU represents a contingent right to one share of common stock and will be settled in shares on each vesting date. The RSUs vest 50% on October 1, 2026 and the remaining 50% on October 1, 2027, subject to continued service. After the grant the reporting person beneficially owns 992,489 shares directly and 10,697 shares indirectly via the Cowan Investment Nominee Trust, which the filer disclaims except for any pecuniary interest.
Douglas Carr, SVP Finance & Operations reported a small, automated sale of company stock to cover tax withholding related to restricted stock unit vesting. On 09/08/2025 he disposed of 263 shares of Century Therapeutics, Inc. (IPSC) at $0.50 per share, leaving 405,423 shares beneficially owned in a direct capacity.
The Form 4 states the sales were automatic and not at the reporting person’s discretion, made solely to satisfy tax-withholding obligations. The filing is signed by the reporting person on 09/10/2025.
Brent Pfeiffenberger, President and CEO and Director of Century Therapeutics, Inc. (IPSC), reported a small automatic sale of common stock on 09/08/2025 to satisfy tax withholding related to the vesting of restricted stock units. The Form 4 shows 488 shares were sold at $0.50 per share, and following the reported transaction the reporting person beneficially owns 3,268,909 shares, held directly. The filing states the sales were automatic to cover tax obligations and not at the reporting person’s discretion.
Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, Inc. (IPSC), reported transactions on Form 4 showing an automatic sale of 539 shares of common stock on 09/08/2025 at a price of $0.50 per share to satisfy tax withholding related to the vesting of restricted stock units. After the reported sale, Mr. Russotti is shown as directly owning 391,508 shares and indirectly owning 92,773 shares through the Gregory Russotti 2021 Family Trust. The filing was signed by an attorney-in-fact on 09/10/2025. The Form 4 notes the sales were automatic and not made at the reporting person's discretion.
Century Therapeutics (IPSC) filed a Form 144 reporting a proposed sale of 488 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $243.95. The shares were acquired on 09/05/2025 as a restricted stock vesting event and payment is listed as compensation. The filer indicates the approximate date of sale as 09/08/2025 and cites NASDAQ as the exchange. The filing also discloses two sales by the same person in the past three months: 475 shares sold on 06/09/2025 for $295.50 and 30,745 shares sold on 08/18/2025 for $17,521.58. The notice includes the standard representation that the seller has no undisclosed material adverse information.
Century Therapeutics, Inc. (IPSC) Form 144 notice reports a proposed sale of 539 shares of common stock held by an individual through Fidelity Brokerage Services, with an aggregate market value of $269.45 and an approximate sale date of 09/08/2025 on NASDAQ. The securities were acquired on 09/05/2025 through restricted stock vesting from the issuer and were paid as compensation. The filer also reports prior dispositions in the past three months: 526 shares sold on 06/09/2025 for gross proceeds of $327.22. The notice includes the filer’s certification that no undisclosed material adverse information is known.
Century Therapeutics, Inc. received a deficiency letter from Nasdaq after its closing bid price fell below the $1.00 minimum over the last 30 consecutive business days, triggering a 180-day compliance period that ran to August 26, 2025. Nasdaq determined the company otherwise met market value and initial listing requirements for The Nasdaq Capital Market and accepted the company's plan to cure the deficiency, including a possible reverse stock split. On August 27, 2025 Nasdaq approved Century's transfer from The Nasdaq Global Select Market to The Nasdaq Capital Market and the company's common stock continues to trade under the symbol IPSC. The filing notes the transfer became effective at the opening of business on August 27, 2025, although one date in the text appears truncated.
Century Therapeutics (IPSC) filing notifies a proposed sale under Rule 144 of 30,745 common shares with an aggregate market value of $17,521.58. The shares represent restricted stock that vested and were acquired on 08/15/2025 and the filer intends to sell on or about 08/18/2025 through Fidelity Brokerage Services on NASDAQ. The filing shows 86,389,098 shares outstanding for the issuer. It also discloses a prior sale by the same person of 475 shares on 06/09/2025 for $295.50. The acquisition payment is listed as compensation. The signer certifies no undisclosed material adverse information.
Brent Pfeiffenberger, President and CEO and a director of Century Therapeutics, Inc. (IPSC), received a grant of 1,587,614 restricted stock units (RSUs) on 08/14/2025. Each RSU converts into one share of common stock and will settle in shares on vesting. The RSUs vest 50% on August 14, 2027 and the remaining 50% on August 14, 2028, each tranche conditioned on continued service through the vesting date. The reported transaction shows an acquisition at a reported price of $0 and indicates 3,269,397 shares beneficially owned by the reporting person after the transaction. The Form 4 was filed for this single reporting person and signed by an attorney-in-fact on 08/18/2025.
FAQ
What is the current stock price of Century Therapeutics (IPSC)?
What is the market cap of Century Therapeutics (IPSC)?
